Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,188 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HER2-normal Clear all

Conditions: Breast Cancer, Lung Cancer, Ovarian Cancer
Interventions: HER-2/neu peptide vaccine, sargramostim; Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, HER2 Negative Breast Adenocarcinoma, Hormone Receptor Positive Breast Adenocarcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Unilateral Breast Carcinoma
Interventions: Abemaciclib, Niraparib Tosylate Monohydrate; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification
Interventions: PRT2527; Drug
Lead sponsor: Prelude Therapeutics Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Denver, Colorado • Celebration, Florida • Sarasota, Florida + 4 more

Conditions: HER2-expressing Cancers
Interventions: ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more

Conditions: Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
Interventions: BYL719, Paclitaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Lafayette, Indiana

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Disitamab vedotin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 120
States / cities: Daphne, Alabama • Foley, Alabama • Mobile, Alabama + 96 more

Conditions: Breast Neoplasms
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastases, Brain
Interventions: capecitabine, lapatinib, trastuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 17
States / cities: Goodyear, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 14 more

Conditions: Breast Cancer, Tumor, Breast, Breast Tumor, Malignant Neoplasm of Breast, Mammary Cancer, Mammary Neoplasm, Mammary Neoplasms, Human, Neoplasm, Breast
Interventions: HTR2 T Cells; Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2044
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Triple Negative Breast Neoplasms, Breast Cancer
Interventions: Pembrolizumab, Mifepristone; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Capecitabine and Neratinib.; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Breast Cancer, Breast Carcinoma, Breast Tumors, Malignant Neoplasm of Breast
Interventions: Paclitaxel, Alisertib; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Including Dallas and Austin, Texas

Conditions: Breast Cancer, Cancer
Interventions: Venetoclax, Capecitabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 11
States / cities: Joliet, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 7 more

Conditions: Metastatic Breast Cancer
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 194 participants
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Interventions: ctDNA-Guided Treatment Strategy; Device
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 50
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more

Conditions: Breast Neoplasms
Interventions: BIBW 2992; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 6
States / cities: Scottsdale, Arizona • Encinitas, California • Santa Monica, California + 3 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Galunisertib, Laboratory Biomarker Analysis, Paclitaxel; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Neoplasms
Interventions: Carboplatin, Docetaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 16
States / cities: Fullerton, California • Los Angeles, California • San Luis Obispo, California + 13 more

Conditions: Breast Cancer
Interventions: Docetaxel, Trastuzumab, Carboplatin, Bevacizumab, 5-Fluorouracil, Epirubicin, Cyclophosphamide; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 3,509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 393
States / cities: Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 272 more

Conditions: Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Interventions: PDR001, ACZ885, CJM112, TMT212, EGF816; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Breast Cancer, Metastatic Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions: Fulvestrant, Anastrozole, Abemaciclib; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 1
States / cities: Orange, California

Conditions: Estrogen Receptor-positive Breast Cancer, Gastrinoma, Glucagonoma, HER2-negative Breast Cancer, Insulinoma, Mucositis, Oral Complications, Pancreatic Polypeptide Tumor, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Islet Cell Carcinoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Renal Cell Cancer
Interventions: Everolimus; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Breast Cancer
Interventions: trastuzumab, laboratory biomarker analysis, adjuvant therapy, quality-of-life assessment; Biological · Other · Procedure
Lead sponsor: Cynthia Owusu, MD; Other
Eligibility: 60 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 11
States / cities: Miami, Florida • Winston-Salem, North Carolina • Cleveland, Ohio + 3 more

Conditions: Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
Interventions: ABBV-400, Itraconazole (ITZ), Bevacizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 20
States / cities: Duarte, California • San Francisco, California • Aurora, Colorado + 15 more

Search by objective public record fields.

Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

A Study of PRT2527 in Participants With Advanced Solid Tumors

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Trastuzumab in Treating Older Women With Early-Stage Breast Cancer

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400